FDA’s Office of Minority Health Seeks to Improve Safety

Posted on January 16, 2013

A new interview highlights the efforts of the Food and Drug Administration’s Office of Minority Health.  In it, the director of this branch of the FDA explains how her office attempts to analyze how medical items could have different impacts on certain minority sections of the population.  She points to warfarin as one drug that has different effects depending on the ethnicity of the individual receiving the treatment. She also says that clinical trials can be improved by getting women and minorities more involved, as doing otherwise means that risks to certain people might go undetected until the repercussions are made known outside of a controlled setting.

Click here to learn more about the office.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.
*Required Fields